Published in Mediterr J Hematol Infect Dis on August 09, 2012
Regulatory T-cells in chronic lymphocytic leukemia: actor or innocent bystander? Am J Blood Res (2013) 0.80
Autoimmune cytopenias in chronic lymphocytic leukemia. Clin Dev Immunol (2013) 0.77
Antibody Drug Conjugate bioinformatics: drug delivery through the letterbox. Comput Math Methods Med (2013) 0.76
Control of regulatory T cell development by the transcription factor Foxp3. Science (2003) 40.32
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol (2003) 38.57
Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol (1995) 29.42
CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med (1998) 19.03
Regulatory T cells and immune tolerance. Cell (2008) 18.77
CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med (2006) 14.33
CD4+ CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol (2002) 12.73
Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol (1998) 11.26
CD4+CD25high regulatory cells in human peripheral blood. J Immunol (2001) 11.25
T cell growth factor receptors. Quantitation, specificity, and biological relevance. J Exp Med (1981) 10.66
Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev (2006) 10.24
Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med (2007) 10.00
Chronic lymphocytic leukemia. N Engl J Med (2005) 9.99
Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol (2002) 9.18
Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med (2004) 8.98
Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med (2006) 8.41
A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3. Nat Immunol (2005) 6.77
Natural regulatory T cells in infectious disease. Nat Immunol (2005) 6.49
Cell interactions in the induction of tolerance: the role of thymic lymphocytes. Immunology (1970) 6.06
Control of intestinal inflammation by regulatory T cells. Immunol Rev (2001) 4.73
TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. Blood (2006) 4.63
Selection of Foxp3+ regulatory T cells specific for self antigen expressed and presented by Aire+ medullary thymic epithelial cells. Nat Immunol (2007) 4.21
Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity (2004) 4.11
Regulatory T cells: how do they suppress immune responses? Int Immunol (2009) 3.58
Regulatory T cells in cancer. Blood (2006) 3.56
X-linked lymphoreticular disease in the scurfy (sf) mutant mouse. Am J Pathol (1991) 3.16
Human CD4+CD25+ regulatory T cells. Semin Immunol (2004) 3.13
Human regulatory T cells: role in autoimmune disease and therapeutic opportunities. Immunol Rev (2008) 2.86
Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood (2005) 2.81
Defective suppressor function of human CD4+ CD25+ regulatory T cells in autoimmune polyglandular syndrome type II. J Exp Med (2004) 2.73
Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy. Nat Rev Cancer (2007) 2.68
Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T regulatory cells. Blood (2004) 2.58
Human regulatory T cells and their role in autoimmune disease. Immunol Rev (2006) 2.56
Regulatory T cells and cancer. Curr Opin Immunol (2007) 2.41
Decreased FOXP3 levels in multiple sclerosis patients. J Neurosci Res (2005) 2.39
TGF-beta 1 prevents the noncognate maturation of human dendritic Langerhans cells. J Immunol (1999) 2.05
Mechanisms of immune suppression by interleukin-10 and transforming growth factor-beta: the role of T regulatory cells. Immunology (2006) 2.03
How do regulatory T cells work? Scand J Immunol (2009) 2.02
Functional defect of regulatory CD4(+)CD25+ T cells in the thymus of patients with autoimmune myasthenia gravis. Blood (2004) 1.90
The role of IL-10 and TGF-beta in the differentiation and effector function of T regulatory cells. Int Arch Allergy Immunol (2002) 1.84
Regulation of immune responses by T cells. N Engl J Med (2006) 1.76
Enhanced formation and survival of CD4+ CD25hi Foxp3+ T-cells in chronic lymphocytic leukemia. Leuk Lymphoma (2009) 1.65
Imbalance of regulatory T cells in human autoimmune diseases. Immunology (2006) 1.64
TGF-beta1 regulation of dendritic cells. Microbes Infect (1999) 1.60
Interleukin-2 deficient mice: a new model to study autoimmunity and self-tolerance. Immunol Rev (1995) 1.58
Role of regulatory T cells in human diseases. J Allergy Clin Immunol (2005) 1.52
Abnormal T-cell function in B-cell chronic lymphocytic leukaemia. Leuk Lymphoma (2003) 1.50
CTLA-4 regulates tolerance induction and T cell differentiation in vivo. J Immunol (1998) 1.45
Cornerstone of peripheral tolerance: naturally occurring CD4+CD25+ regulatory T cells. Trends Immunol (2004) 1.42
Control of autoimmune myocarditis and multiorgan inflammation by glucocorticoid-induced TNF receptor family-related protein(high), Foxp3-expressing CD25+ and CD25- regulatory T cells. J Immunol (2006) 1.32
Regulatory T-cell number is increased in chronic lymphocytic leukemia patients and correlates with progressive disease. Leuk Res (2010) 1.21
Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia. Cancer (2011) 1.19
T-regulatory cell modulation: the future of cancer immunotherapy? Br J Cancer (2009) 1.13
Characterization of regulatory T cells in patients with B-cell chronic lymphocytic leukemia. Oncol Rep (2008) 1.10
Definition and characterization of the systemic T-cell dysregulation in untreated indolent B-cell lymphoma and very early CLL. Blood (2011) 1.09
Immune dysfunction in chronic lymphocytic leukemia T cells and lenalidomide as an immunomodulatory drug. Haematologica (2009) 0.96
A shorter time to the first treatment may be predicted by the absolute number of regulatory T-cells in patients with Rai stage 0 chronic lymphocytic leukemia. Am J Hematol (2012) 0.94
The high frequency of T regulatory cells in patients with B-cell chronic lymphocytic leukemia is diminished through treatment with thalidomide. Leukemia (2007) 0.92
Regulatory T-cell adoptive immunotherapy: potential for treatment of autoimmunity. Expert Rev Clin Immunol (2011) 0.88
Regulatory T cells predict the time to initial treatment in early stage chronic lymphocytic leukemia. Cancer (2010) 0.87
Circulating regulatory T cells in "clinical" monoclonal B-cell lymphocytosis. Int J Immunopathol Pharmacol (2012) 0.85
Applying a new generation of genetic maps to understand human inflammatory disease. Nat Rev Immunol (2005) 0.84
Targeting regulatory T cells for anticancer therapy. Mini Rev Med Chem (2011) 0.81
Expansion of regulatory T cells in B chronic lymphocytic leukemia: enhanced 'brakes' on host immunity. Leuk Lymphoma (2009) 0.80
BRAF mutations in hairy-cell leukemia. N Engl J Med (2011) 7.05
Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med (2012) 5.87
Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology. Physiol Rev (2008) 2.92
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood (2010) 2.84
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood (2008) 2.68
Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. Blood (2011) 2.44
Role of helical CT in diagnosis of gallstone ileus and related conditions. AJR Am J Roentgenol (2005) 2.43
Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. Blood (2011) 2.37
Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med (2014) 2.33
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol (2010) 2.27
Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol (2010) 2.25
Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network. J Clin Oncol (2007) 2.14
Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. Blood (2011) 2.04
Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. Haematologica (2012) 1.98
The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development. J Exp Med (2012) 1.90
Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. Blood (2012) 1.88
High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study. Leuk Lymphoma (2012) 1.77
Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients. J Clin Oncol (2010) 1.76
Prevalence of hepatitis C virus infection in lymphoproliferative diseases other than B-cell non-Hodgkin's lymphoma, and in myeloproliferative diseases: an Italian Multi-Center case-control study. Haematologica (2004) 1.72
Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood (2011) 1.69
CD39 and control of cellular immune responses. Purinergic Signal (2007) 1.68
Azacitidine for the treatment of patients with acute myeloid leukemia: report of 82 patients enrolled in an Italian Compassionate Program. Cancer (2011) 1.67
Anemia in Hodgkin's lymphoma: the role of interleukin-6 and hepcidin. J Clin Oncol (2010) 1.66
Melphalan 200 mg/m(2) versus melphalan 100 mg/m(2) in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study. Blood (2009) 1.65
Oxidative stress effects on endothelial cells treated with different athletes' sera. Med Sci Sports Exerc (2012) 1.62
Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multicenter case-control study. Blood (2003) 1.62
Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study. Leuk Lymphoma (2011) 1.60
TfR2 localizes in lipid raft domains and is released in exosomes to activate signal transduction along the MAPK pathway. J Cell Sci (2006) 1.55
ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. J Clin Oncol (2009) 1.54
Habitual salt intake and risk of gastric cancer: a meta-analysis of prospective studies. Clin Nutr (2012) 1.54
Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients. Leuk Lymphoma (2007) 1.54
Alteration of BIRC3 and multiple other NF-κB pathway genes in splenic marginal zone lymphoma. Blood (2011) 1.53
Reduced intensity conditioning for allograft after cytoreductive autograft in metastatic breast cancer. Lancet (2005) 1.53
Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up. J Clin Oncol (2011) 1.53
Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma. Haematologica (2002) 1.47
Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood (2007) 1.47
Bendamustine in relapsed/refractory multiple myeloma: the "real-life" side of the moon. Leuk Lymphoma (2015) 1.46
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. J Clin Oncol (2014) 1.44
Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib. Leuk Res (2011) 1.42
FISH analysis reveals frequent co-occurrence of 4q24/TET2 and 5q and/or 7q deletions. Leuk Res (2011) 1.39
Efficacy of bortezomib in systemic extramedullary localizations of multiple myeloma. Clin Adv Hematol Oncol (2012) 1.38
Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood (2004) 1.37
Intravascular large B cell lymphoma: when lymphoma is suspected but routine diagnostic work-up is negative. Leuk Lymphoma (2009) 1.37
Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance. J Transl Med (2009) 1.35
CD38/CD31, the CCL3 and CCL4 chemokines, and CD49d/vascular cell adhesion molecule-1 are interchained by sequential events sustaining chronic lymphocytic leukemia cell survival. Cancer Res (2009) 1.34
CD38 and chronic lymphocytic leukemia: a decade later. Blood (2011) 1.33
High prevalence of hepatitis B virus infection in B-cell non-Hodgkin's lymphoma. Haematologica (2006) 1.28
High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program. Br J Haematol (2008) 1.23
Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome. Clin Cancer Res (2009) 1.22
The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia. Haematologica (2013) 1.21
Regulatory T-cell number is increased in chronic lymphocytic leukemia patients and correlates with progressive disease. Leuk Res (2010) 1.21
Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes. Clin Cancer Res (2009) 1.21
CD38 orchestrates migration, survival, and Th1 immune response of human mature dendritic cells. Blood (2005) 1.20
Effect of essential oils on pathogenic bacteria. Pharmaceuticals (Basel) (2013) 1.20
The viral load of Epstein-Barr virus (EBV) DNA in peripheral blood predicts for biological and clinical characteristics in Hodgkin lymphoma. Clin Cancer Res (2011) 1.18
Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: a retrospective survey of 50 patients. Cancer (2011) 1.18
Nicotinamide blocks proliferation and induces apoptosis of chronic lymphocytic leukemia cells through activation of the p53/miR-34a/SIRT1 tumor suppressor network. Cancer Res (2011) 1.13
Positive effects on hematopoiesis in patients with myelodysplastic syndrome receiving deferasirox as oral iron chelation therapy: a brief review. Leuk Res (2010) 1.11
CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death. Blood (2011) 1.09
Biological and clinical relevance of miRNA expression signatures in primary plasma cell leukemia. Clin Cancer Res (2013) 1.09
Chemical composition and antimicrobial activity of the essential oils from three chemotypes of Origanum vulgare L. ssp. hirtum (Link) Ietswaart growing wild in Campania (Southern Italy). Molecules (2009) 1.08
CD38 and CD157 as receptors of the immune system: a bridge between innate and adaptive immunity. Mol Med (2007) 1.08
Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA. Eur J Haematol (2009) 1.07
Arsenic trioxide and breast cancer: analysis of the apoptotic, differentiative and immunomodulatory effects. Breast Cancer Res Treat (2002) 1.07
Biological functions of ecto-enzymes in regulating extracellular adenosine levels in neoplastic and inflammatory disease states. J Mol Med (Berl) (2013) 1.06
Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma. Hematol J (2004) 1.03
Salvage therapy with lenalidomide and dexamethasone in relapsed primary plasma cell leukemia. Leuk Res (2008) 1.03
Lenalidomide and its role in the management of multiple myeloma. Expert Rev Anticancer Ther (2008) 1.03
Oct-4+/Tenascin C+ neuroblastoma cells serve as progenitors of tumor-derived endothelial cells. Cell Res (2011) 1.02
Glutathione S-transferase P1 genotype and prognosis in Hodgkin's lymphoma. Clin Cancer Res (2005) 1.01
Chronic lymphocytic leukemia after chronic myeloid leukemia in the same patient: two different genomic events and a common treatment? J Clin Oncol (2012) 1.01
Expression of ribosomal and translation-associated genes is correlated with a favorable clinical course in chronic lymphocytic leukemia. Blood (2002) 1.00
Compositional study and antioxidant potential of Ipomoea hederacea Jacq. and Lepidium sativum L. seeds. Molecules (2012) 1.00
The monocytic population in chronic lymphocytic leukemia shows altered composition and deregulation of genes involved in phagocytosis and inflammation. Haematologica (2013) 1.00
Transcriptional characterization of a prospective series of primary plasma cell leukemia revealed signatures associated with tumor progression and poorer outcome. Clin Cancer Res (2013) 0.98
Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma. Haematologica (2002) 0.98
Transferrin receptor 2 is frequently expressed in human cancer cell lines. Blood Cells Mol Dis (2007) 0.98
Outcome of therapy-related myeloid neoplasms treated with azacitidine. J Hematol Oncol (2012) 0.97
Chronic lymphocytic leukemia microenvironment: shifting the balance from apoptosis to proliferation. Haematologica (2009) 0.97
In-vitro and in-vivo validation of ethnopharmacological uses of methanol extract of Isodon rugosus Wall. ex Benth. (Lamiaceae). BMC Complement Altern Med (2014) 0.97